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ABSTRACT
Transplantation of mismatched allografts in irradiated recipients results in lethal graft- versus-host disease
(GVHD). In our study, pretransplantation donor treatment with CpG, administered either alone or emulsified
in incomplete Freund’s adjuvant, efficiently prevented GVHD in sublethally irradiated recipients of haploident-
ical (H-2b intoH-2b/d) and fullymismatched (H-2b intoH-2d) allografts. CpG treatment of donormice caused an
accumulation of double-positive CD11bGr-1 cells in their blood and spleens, whereas treatment withCpG1IFA
resulted in an even greater accumulation of these cells. Isolated CD11b1 cells from the spleens of CpG1IFA-
treated mice efficiently suppressed alloreactivity in vitro (. 92%), as determined by co-culturing these cells
in mixed lymphocyte reactions. After CpG1IFA treatment, a T cell–depleted fraction enriched with
CD11b1Gr-11 cells, acting as myeloid suppressor cells, was able to efficiently prevent GVHD induced by naı¨ve
T cells in the sublethally irradiated recipients: 20/21 mice remained GVHD-free survivors for more than 200
days. Splenocytes from CpG1IFA-treated mice displayed enhanced interleukin (IL)-6, IL-10, and interferon-
g production, reduced T cell allogeneic and mitogenic responses, as well as failure of T cells to induce
GVHD. In summary, CpG treatment led to impaired T cell function, enrichedmyeloid suppressor cells and reg-
ulatory cytokine production, which together appear to suppress alloreactivity and protect against the develop-
ment of GVHD. We hypothesize that similar immunoregulatory effects could be applied experimentally in
a clinical setting when inhibition of alloreactivity is required in recipients of stem cell allografts.
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Synthetic oligodeoxynucleotides (ODNs) contain-
ing unmethylated CpGmotifs (CpG) mimic bacterial/
viral DNA sequences and are recognized as nonself by
Toll-like receptors (TLRs) expressed on various im-
mune cells of mammalian and other vertebrates [1,2].
The TLRs are key components of the innate immune
system, and ligation of CpG to these receptors leads to
activation of B lymphocytes, natural killer (NK) cells,
and antigen-presenting cells, such as macrophagesand dendritic cells (DCs) [2-6]. CpG is known to be
a potent nonspecific immunomodulator that also plays
an important role in adaptive immunity directed to
achieve Th 1-mediated immune responses after vacci-
nation with viral- or cancer-derived peptides [7-13], as
well as in modification of Th-2– associated disorders
toward a Th 1 response in allergies and autoimmune
diseases [14-16]. CpG’s immunomodulatory effect
and ability to activate various immune cell subsets
led us to investigate its capability to modify the973
974 S. Morecki et al.complex network of cell subpopulations and the Th 1/
Th 2-type cytokine pattern of cell sources currently
being applied in clinical protocols of allogeneic cell
therapy and induction of hematopoietic chimerism.
Allogeneic cell therapy and donor lymphocyte infusion
after allogeneic stem cell transplantation in the clinic,
as well as in experimental models, are frequently asso-
ciated with acute and chronic graft-versus-host disease
(GVHD), which diminishes the benefit of the alloge-
neic reaction required to achieve an efficient response
in patients with genetic disorders and malignant dis-
eases [17-21]. Although most of the strategies aimed
at preventing or modifying the intensity of GVHD
are based on posttransplantation immunosuppression,
the only effective modality to prevent GVHD requires
removal of donor T cells before transplantation or the
use of only purified CD341 stem cells. Unfortunately,
elimination of T cells results in increased risk of graft
rejection unless conditioning is myeloablative and
highly immunosuppressive, leading to delayed im-
mune reconstitution, with a concomitant increase in
opportunistic infections and increased risk of relapse
of the underlying malignant disease [22,23]. Recently
we have shown that pretransplantation donor treat-
ment with various immunomodulators, such as com-
plete Freund’s adjuvant (CFA), lipopolysaccharide
(LPS), and CpG, can indeed prevent the development
of GVHD in sublethally irradiated host mice inocu-
lated with haploidentical donor cells [24].
The present study aimed to clarify how CpG-in-
duced immunomodulation occurs and to ascertain
the role of cells and cytokines in the prevention of
and/or protection against alloreactivity in vitro and
in vivo. This strategy was also tested on another donor
genotype in an experimental model of GVHD across
fully mismatched major histocompatibility complex
(MHC) barriers.
MATERIALS AND METHODS
Mice
Female BALB/c H-2d (BALB), C57BL/6 H-2b
(C57), and (BALB/c  C57BL/6)F1 H-2d/b (F1) mice
age 10-12 weeks, weighing 22-24 g, were used in this
study. All mice were purchased from Harlan, Israel
and maintained in the animal facility of the Hadassah
University Hospital in full compliance with the regula-
tions for the protection of animal rights.
Donor Pretreatment
CpG (ODN #1826) or non-CpG control (ODN
#2138) (Coley Pharmaceutical Group, Kanata, Can-
ada) at a dose of 100 mg, either alone or as an emulsion
in incomplete Freund’s adjuvant (IFA) (Difco Labora-
tories, Detroit, MI), was injected subcutaneously into
2 sites in naive mice (0.1 mL/site). The day of spleno-
cyte harvest is specified in each experiment.Experimental Design for GVHD Induction
F1 recipient mice were conditioned with total body
irradiation of 5.5 Gy, using a 6-MeV linear accelerator
at a dose rate of 1.9Gy/min.The nonlethally irradiated
recipients were inoculated intravenously 48 h later
with 20-40 106 splenocytes derived from either naı¨ve
or pretreated mice, as specified in each experiment.
Flow Cytometry Analysis
For fluorescence-activated cell sorting (FACS)
analysis, anti-mouse CD80 (phycoerythrin [PE]),
CD86 (PE), CD25 (PE), CD11c (antigen-presenting
cell [APC] or fluorescein isothiocyanate [FITC]),
CD45R/B220 (PE), CD3 (FITC), CD19 (APC), Gr-
1/Ly6-G (FITC), and CD11b/Mac-1 (peridinin-chlo-
rophyll-protein complex) were purchased from BD
Biosciences (San Diego, CA). Anti-mouse CD14
(PE), F4/80 (APC), CD8 (APC), and TLR9 (FITC)
were purchased from eBioscience (San Diego, CA).
Before fluorescence staining, red blood cells were lysed
with mouse erythrocyte lysing buffer (R&D Systems,
Minneapolis, MN). Splenocytes were washed with
phosphate-buffered saline (PBS) (Biological Indus-
tries, Beit Haemek, Israel) and resuspended in staining
buffer (1% bovine serum albumin [purchased from
Sigma-Aldrich, Rehovot, Israel] and 0.03% sodium
azide in PBS). Splenocytes (5  105) were incubated
for 5 minutes with mouse Fc blocker (CD32/16) anti-
body (eBioscience) to prevent nonspecific staining.
Staining with specified antibody was carried out for
20 minutes on ice, then washed with staining buffer,
fixed for 30 minutes with 1% formaldehyde solution
in PBS, and resuspended in PBS for reading on the
next day.
For intracellular staining, splenocytes after lysis
(5  105) were fixed with 4% formaldehyde solution
in PBS for 20 minutes at room temperature, washed
with permeabilization buffer (0.1% saponin, 0.09%
sodium azide in distilled water) and then stained with
TLR9 antibody for 20 min. All samples were analyzed
with a FACSCalibur flow cytometer and CellQuest
software (BD Biosciences).
Chimerism Assay
The mice were anesthetized (100 mg/kg ketamine
and 1.2 mg/kg dihydrobenzperidol administered intra-
peritoneally), and blood samples were obtained from
the retro-orbital sinus of the eye. Peripheral blood
mononuclear cells were isolated using lympholyte-M
gradient (Cedar Lane Laboratories, Ontario, Canada),
anddonor cell percentagesweredetectedbyFACSanal-
ysis using PE anti-H-2d antibodies (BD Biosciences).
The percentage of H-2b donor cells in the F1 (H-2
d/b)
hosts was determined by measuring the disappearance
of host cells carryingH-2d antigen, according to the fol-
lowing formula: 100%-%H-2d1 cells5%H-2b1 cells.
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hosts was determined directly by using PE anti-H-2d
antibodies.
Magnetic Cell Sorting
Magnetic cell separation was carried out from sus-
pensions of splenocytes derived from either naı¨ve or
pretreated C57 mice, as specified in each experiment.
T cells were isolated by depletion of non-T cells (neg-
ative selection) with the mouse Pan T Cell Isolation
Kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
The T cell–depleted (TCD) fraction (negative selec-
tion) was obtained through T cell depletion with
mouse CD90 (Thy 1.2) MicroBeads (Miltenyi Biotec).
The CD11b1 fraction (positive selection) was isolated
with BD IMag Anti-Mouse CD11b Particles-DM (BD
Bioscience). All isolations were carried out according
to the manufacturers’ protocols. In brief, for isolated
T cells and TCD fractions, splenocytes were labeled
with the corresponding antibody and then loaded
onto a MACS LS column placed in the magnetic field
of a MACS cell separator (Miltenyi Biotec). For
CD11b1 fraction isolation, splenocytes were labeled
and then placed in a test tube within the magnetic field
of the BD IMag cell separator.
Mixed Lymphocyte Reaction
The mixed lymphocyte reaction (MLR) and sup-
pressive activity were carried out as described previ-
ously [25], with minor changes. In brief, 5  105
isolated T cells derived from naı¨ve or pretreated
mice were incubated for 4 days with 1  106 irradiated
(50 Gy) splenocytes in 0.2-0.25 mL of medium con-
taining 5%human inactivated AB1 serum.To evaluate
suppressive activity, 5  105 irradiated (15 Gy)
CD11b1 or CD11b2 cells from either naı¨ve or
CpG1IFA-pretreated mice were added as a co-culture
to the MLR test, as specified in each experiment.
After 72 h, cultures were pulsed with 185 GBq/
mmol 1m Ci[methyl3H]thymidine (Amersham, GE
Healthcare, UK) for 18 h, and response was monitored
by measuring radioactivity uptake (in CPM). The per-
centage of suppression was calculated, after subtrac-
tion of syngeneic response, by the following formula:
100 - [CPM of allogeneic response in the presence
of co-cultured isolated CD11b2 or CD11b1 cells/
CPM of allogeneic response in the presence of
co-cultured naı¨ve unseparated cells]  100.
Mitogenic Response
Splenocytes (2-4 105) isolated from naı¨ve or pre-
treated C57 mice were cultured in a flat 96-well plate
(Nunc, Roskilde, Denmark) with 10 mg/mL of conca-
navalin-A (Con-A) or 2 ng/mL of phorbol 12-myris-
tate acetate (PMA), and 0.2 mmol of calciumionophore (Ca11 Iono) or 50 mg/mL of LPS (Sigma-
Aldrich, Rehovot, Israel), or 1 mg/mL of mouse anti-
CD3 monoclonal antibody (clone 2C11, kindly
provided by G. Gross, Migal, Kiryat Shmona, Israel)
in 0.2mL of RPMI 1640 supplemented with 10% fetal
bovine serum (Gibco, Grand Island, NY), 2mmol/L of
glutamine, 100 mg/mL of streptomycin, 100 U/mL of
penicillin, 0.25 mg/mL of amphotericin B, and 5 
1025 M of 2-mercaptoethanol (Sigma-Aldrich,
Rehovot, Israel). After 48 h, cultures were pulsed
with 1mCi [methyl3H]thymidine for 18 h and then
harvested. Response was monitored by measuring
radioactivity uptake.
Cytokine Profile
C57 splenocytes from either naı¨ve mice or mice
pretreated with CpG alone or CpG1IFA were de-
pleted of red blood cells with mouse erythrocyte lysing
buffer, washed with PBS, and resuspended in RPMI
1640 supplemented with 10% fetal bovine serum
(Gibco), 2 mmol of glutamine, 100 mg/mL of strepto-
mycin, 100 U/mL of penicillin, 0.25 mg/mL of
amphotericin B (Biological Industries), and 5  1025
M of 2-mercaptoethanol (Sigma-Aldrich). Cells
(4 106 cell/mL/well) were incubated with or without
2.5 mg/mL of Con-A for 48 h in a 24-well plate in a hu-
midified incubator at 37C and 5%CO2. Supernatants
were collected and kept frozen at 280C until testing
by enzyme-linked immunosorbent assay (ELISA)
(Ready-SET-Go! Kit; eBioscience), according to the
manufacturer’s directions. The following cytokines
were tested: interleukin (IL)-2, IL-4, IL-6, IL-10,
interferon (IFN)-g, and tumor necrosis factor-a.
Absorption was measured using a microplate reader
(Spectra Fluor Plus; Tecan, Durham, NC) at 450
nm after the value of the wavelength (570 nm) was
subtracted.
Statistical Analysis
The Kaplan-Meier method [26] was used to calcu-
late the probability of survival as a function of time
after cell inoculation. The statistical significance
between pairs of Kaplan-Meier curves was evaluated
using the log-rank test [27]. Statistical significance in
the difference of mitogenic response and cytokine pro-
duction observed in experimental groups compared
with control groups was evaluated using the standard
2-tailed, unpaired Student t-test.
RESULTS
Prevention of GVHD in C57 Mice by
PretransplantationTreatment of FullyMismatched
BALB Donor Mice
Injection of CpG1IFA into BALB donor mice re-
sulted in enlarged spleens and increased numbers of
splenocytes, which reached a maximum on day 6 after
976 S. Morecki et al.injection (333 1066 68 cells vs 93 1066 13 cells in
naı¨ve mice) (data not shown). Treatment of BALB
mice serving as donors for C57 recipients was carried
out 6 days before transplantation. Inoculation with
40  106 splenocytes from naı¨ve BALB mice into sub-
lethally irradiated C57 recipients induced severe
GVHD, with 100% mortality (14/14) between days
8 and 33 after cell inoculation. In contrast, inoculation
with 40 106 splenocytes from BALB donor mice pre-
treated with CpG1IFA did not cause GVHD in C57
recipients; 88% (15/17) of the recipients remained
healthy and free of GVHD for more than 200 days.
In 5/5 mice tested for chimerism on day 100 after
cell inoculation, .70% donor-type cells were docu-
mented, suggesting the induction of stable chimerism
Table 1. Effect of Pretransplantation Donor Treatment with CpG on
GVHD Induction in C57 Host Mice Inoculated with BALB Splenocytes
Donor
Pretreatment
(BALB)
Survival,
Days,Median
(Range), n
GVHD-Related
Death
Disease-Free
Survivors
— 14 (8-33), 14 14 0
IFA 34 (8-131), 14 14 0
Non-CpG1IFA 9 (7-55), 7 7 0
CpG1IFA .200 (89-.200), 17 2 15
Sublethally irradiated (6.5 Gy) C57 mice were inoculated intrave-
nously with 40  106 BALB splenocytes after irradiation.
BALB donors were treated with CpG1IFA 6 days before spleen
harvest. Results were pooled from 2 independent experiments.
P 5 .00 comparing the CpG1IFA experimental group with all
other groups.rather than rejection (data not shown). Control mice
inoculated with donor cells pretreated with IFA or
non-CpG1IFA died of severe GVHD (median sur-
vival, 9 and 34 days, respectively) (Table 1).
Phenotypic Analysis of Spleen Cells Responding
to CpG
In vivo stimulation of C57 mice with CpG alone
led to a slight rise (7%) in the number of
CD11b1Gr-11 cells in the spleen, compared with
15% after stimulation with CpG emulsified in IFA
(Figure 1). The greatest increase in CD11b1Gr-11
cells was observed 6 days after CpG inoculation and
10 days after CpG1IFA treatment (data not shown).
To characterize the CD11b1Gr-11 cell subpopulation
after CpG1IFA treatment, we isolated CD11b1 cells
by positive selection using magnetic beads and carried
out a detailed phenotypic analysis after gating for
Gr-11 cells in the FACS. The following cell surface
markers were checked and their expression on the
CD11b1Gr-11 cells was determined 10 days after
CpG1IFA treatment: CD80 (8%) and CD86 (5%)
for the detection of co-stimulatory molecules, B220
(10%) for all stages of B lymphocytes, CD11c (5%)
for DCs, CD14 (4%) for detection of the LPS macro-
phage receptor, and F4/80 (3%) expressed on mature
macrophages (Figure 2). Cell surface markers indica-
tive of T lymphocytes were very low: 7% CD3 and
0% CD8 (data not shown). Taken altogether, the
CD11b1Gr-11 cells isolated and gated afterFigure 1.Accumulation of CD11b1/GR-11 cells in spleens of CpG-treatedmice. CpGorCpG1IFAwas injected subcutaneously intoC57mice
6 or 10 days, respectively, before flow cytometry analysis. Injections of non-CpG or non-CpG1IFA or IFA alone served as controls and were
given in parallel to their relevant opposite (ie, CpG vs non-CpG and CpG1IFA vs non-CpG1IFA). The results shown represent 1 experiment
out of 5 experiments conducted.
CpG-Induced Myeloid Suppressor Cells 977Figure 2. Characterization of CD11b1 cells isolated from spleens of GpG1IFA-treated mice. Flow cytometry was carried out on a CD11b1
fraction isolated by magnetic beads from spleens of mice treated with CpG1IFA 10 days earlier. (A) Positive fraction of isolated CD11b cells.
(B) Isolated CD11b cells gated for GR-1 cells. (C)-(H) Various phenotypic markers of the CD11b-isolated Gr-1 gated cells. The results shown
represent 1 experiment out of 3 experiments conducted.CpG1IFA treatment did not carry cell surfacemarkers
that could relate them to any subpopulation of DCs,
T and B lymphocytes, or mature macrophages.
All of the aforementioned phenotypic analyses
were carried out on spleen cells. It was important to
determine whether any major changes also occurred
in cells derived from other tissues. The most promi-
nent change in CD31 cells was found in lymph nodes,
whereas a significant increase (28%) in the percentage
of CD11b1 cells, Gr-11 cells, and double-positive
CD11b-Gr-1 cells was detected in the blood (Figure 3).
No major changes were found in the distribution of
these subpopulations in the bone marrow of treated
mice compared with naı¨ve bone marrow cells (data
not shown).
The Role of CD11b1 Cells in the
Immunoregulation of Alloreactivity
Isolated CD11b1 cells from C57 mice were added
to the MLR of C57-derived cells responding to BALB
splenocytes. CD11b1 cells from naı¨ve mice and from
mice treated with non-CpG1IFA 10 days earlier
caused MLR suppression of 80% and 70%, respec-
tively. The greatest MLR suppression (98%) was in-
duced by CD11b1 cells isolated from mice treatedwith CpG1IFA 10 days earlier. In parallel, the nega-
tive cell fraction (non-CD11b1) caused only weak or
absolutely no suppression, as shown in Table 2.
Similar to the C57-derived cells, CD11b1 cells
from BALB mice suppressed the MLR of BALB cells
responding to C57 splenocytes. Table 3 shows that
co-cultured CD11b1 cells derived from BALB mice
treated with CpG1IFA 6 days earlier strongly sup-
pressed theMLR (92%), whereas CD11b1 cells derived
from naı¨ve or non–CpG1IFA-treated BALB mice
showed significantly less suppressive activity (45% and
55%, respectively). The negative cell fraction (non-
CD11b1) of BALB mice was totally nonsuppressive in
the MLR.
Effect of CpG1IFA Pretreatment on Immunologic
Reactivity In Vitro
Mitogenic and allogeneic responses were tested in
C57 splenocytes from mice treated with CpG1IFA 10
days earlier (Figure 4). Compared with naı¨ve spleno-
cytes, reduced proliferation was observed in response
to allogeneic stimuli, Con-A, and PMA1Ca11Iono
(response of 41%, 23%, and 16%, respectively),
whereas the responses to anti-CD3 and LPS remained
almost the same as those of the naı¨ve control
978 S. Morecki et al.Figure 3.Distribution of T cells and myeloid cells after CpG treatment. Peripheral blood cells, splenocytes, and lymph node–derived C57 cells
were analyzed by flow cytometry to detect T cells (CD3) and/ormyeloid cells (CD11b andGr-1) 10 days after inoculation of CpG1IFA (100 mg).
Non-CpG1IFA inoculations served as controls. The results shown represent 1 experiment out of 2 experiments conducted.splenocytes (74% and 90%, respectively). The re-
sponses of splenocytes from mice treated with non-
CpG1IFA to all of the mitogenic stimuli tested were
similar to those of naı¨ve cells, except for the response
to PMA1Ca11Iono, which was very low (45%). A sta-
tistically significant difference between CpG1IFA and
non-CpG1IFA treatment was observed only in the
MLR and in the response to Con-A (P 5 .049 and
.016, respectively). These findings indicate that treat-
ment with CpG1IFA affected allogeneic and mito-
genic T cell responses to Con-A but had no effect on
B cell mitogenic response as tested by LPS stimulation.Cytokine Secretion after CpG Treatment
The effect of CpG treatment on cytokine produc-
tion was measured in supernatants of splenocytes de-
rived from C57 mice pretreated 10 or 6 days earlier
with either CpG or non-CpG with or without IFA.
The results, presented in Figure 5, show that secretion
of IL-10 and IL-6 was significantly higher after treat-
ment with CpG than after treatment with non-CpG.
Secretion of IFN-g did not differ significantly after
treatment with CpG and with non-CpG . Inoculation
of CpG or non-CpG emulsified in IFA resulted in sig-
nificantly increased amounts of IL-6 and IL-10 and, toTable 2. Suppression of C57 Anti-BALB Alloreactivity In Vitro by CD11b1 Cells
CD11b2 Cells CD11b1 Cells
Pretreatment of Co-Cultured C57 Cells CPM ± SE % Suppression CPM ± SE % Suppression
None 49,120 ± 1,956 22 13,591 ± 1,149 80
Non-CpG1IFA 71,748 ± 1,840 0 19,091 ± 374 70
CpG1IFA 55,969 ± 11,415 10 1,569 ± 525 98
SE, standard error.
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CD11b2 Cells CD11b1 Cells
Pretreatment of Co-
Cultured BALB Cells CPM ± SE % Suppression CPM ± SE % Suppression
None 65,890 ± 1,458 0 31,610 ± 5,745 45
Non-CpG1IFA 64,617 ± 7,966 0 25,570 ± 3,464 55
CpG1IFA 55,260 ± 10,745 4 4,778 ± 1,552 92
SE, standard error.a lesser degree, of IFN-g in splenocytes derived from
CpG1IFA-treated mice. These findings demonstrate
that treatment with CpG affected cytokines known
to play a role in immunoregulation.
Effect of CpG1IFATreatment on T Cell Reactivity
In Vivo
T cells isolated from C57 donors treated with
CpG1IFA 10 days earlier did not induce GVHD
when inoculated into sublethally irradiated F1 mice.
Almost all of the mice (13/14) remained GVHD-free
for a follow-up period of more than 250 days (Table
4), and only 2/14 mice contained donor cell genotype
when evaluated 80-100 days after cell inoculation.
Control groups of mice inoculated with T cells iso-
lated from naı¨ve C57 donors or donors treated 10
Figure 4. In vitro mitogenic responses of splenocytes pretreated
with CpG1IFA. Splenocytes derived fromC57mice treated with ei-
ther CpG1IFA or non-CpG1IFA 10 days earlier were tested for
various mitogenic responses (LPS, Con-A, PMA1Ca11Iono, and
anti-CD3). Results are presented as response percentage in relation
to 100% response of naı¨ve nontreated splenocytes. Response per-
centages were calculated from 3HTdR uptake in proliferation assays
of 3 days of mitogenic stimulation and 4 days for the MLR of C57-
derived T cells responding to BALB splenocytes. P 5 .049 and .016
for the comparison of non-CpG1IFA and CpG1IFA treatments in
the MLR and in response to Con-A, respectively; P5 .105, .12, and
.235 for the comparison of non-CpG 1IFA and CpG1IFA treat-
ments in response to PMA1Ca11Iono, anti-CD3, and LPS, respec-
tively. The results represent the mean6 standard error of 3 separate
experiments.days earlier with IFA or non-CpG1IFA all died of se-
vere GVHD, with a median survival of 18, 20, and 22
days, respectively (Table 4). Testing of long-term chi-
merism in these control groups was not feasible on day
.80 after T cell inoculation. These findings demon-
strate that treatment with CpG1IFA led to impaired
T cell function, which did not allow an alloreactive
response in vivo or induction of long-term chimerism.
Inhibition of GVHD by a TCD Spleen
Subpopulation Isolated from CpG1IFA-Treated
Mice
Naı¨ve T cells isolated from the spleens of naı¨ve
C57 mice and injected into sublethally irradiated F1
mice led to severeGVHDand 100% (21/21)mortality,
with a median survival of 19 days. The TCD cell frac-
tion isolated from splenocytes derived from C57 mice
treated with CpG1IFA 10 days earlier almost totally
prevented GVHDwhen co-injected with naı¨ve T cells.
The isolated TCD fraction contained CD11b1Gr-11
cells and was negative for Thy-1 and CD3 cells as
tested by FACS analysis (data not shown). The TCD
cell fraction conferred the most efficient protection
against GVHD induction, and 20/21 mice remained
disease-free survivors over a follow-up period of
more than 200 days (Table 5). It is interesting to
note that 14 of the 15 F1 mice tested had 85%-100%
donor-type cells in peripheral blood samples obtained
more than 170 days after cell inoculation, indicating
a stable state of chimerism. In the absence of T cells,
inoculation of TCD cell fraction alone, derived from
either naı¨ve or C57 mice pretreated with CpG1IFA,
did not result in chimerism in the sublethally irradiated
F1 hosts (data not shown). These findings demonstrate
that after CpG1IFA treatment, the cell subpopulation
contains cellular constituents that enable engraftment
and at the same time suppress alloreactivity by the
enriched CD11b1Gr-11 cells in the TCD fraction.
DISCUSSION
We have documented that treatment of donor
mice before allogeneic cell therapy with immunomod-
ulator CpG and, more significantly, with a combina-
tion of CpG 1 IFA led to engraftment with no
GVHD. Challenging mice with CpG resulted in
980 S. Morecki et al.Figure 5.Cytokine secretion after CpG treatment. Splenocytes from C57 mice treated 6 or 10 days earlier with CpG (A) or CpG1IFA (B) were
stimulated with Con-A for 48 h. The cytokine levels in the supernatants of the various cultures were measured. The results indicate P 5 .001,
.007, and .36 for the comparison of CpG versus non-CpG for secretion of IL-10, IL-6, and IFN-g, respectively, and P5 .048, .013, and .076 for
the comparison of CpG1IFA versus non-CpG1IFA for secretion of IL-10, IL-6, and IFN-g, respectively.a reduced number of CD31 cells and accumulation of
CD11b1Gr-11 myeloid suppressor cells (MSCs) able
to suppress allogeneic response in vitro and in vivo.
The overall results of our phenotypic analyses carried
out after in vitro stimulation demonstrate that the
CpG 1826 that we used served as a ligand for TLR9
(data not shown), which is known for its role in provid-
ing signals that trigger innate and adaptive immune re-
sponses. In vivo stimulation led to an increase in the
myeloid cell population expressing both the myeloid
differentiation antigen Gr-1 and the Mac-1 (CD11b)
cell surface markers. The time of splenocyte harvest af-
ter donor treatment was determined by 3 parameters:
(1) maximum increase in the total cell numbers in the
spleen, (2) decrease in number of CD31 cells, and (3)
maximum increase in the number of CD11b1Gr-11
cells. Taken altogether, these parameters were
achieved on day 6 after CpG treatment of C57 donors
or CpG1IFA treatment of BALB/c donors and on day
10 after CpG1IFA treatment of C57 donors. Kinetic
experiments revealed not a constant rate of change,
but rather the existence of a regulatory networktriggered by the CpG stimulus. The ability of this
CD11b1Gr-11 cell population, functioning as
MSCs, to inhibit alloreactivity led us to use it as a donor
cell source for allogeneic cell therapy inmurinemodels
of GVHD across haploidentical and fully mismatched
alloantigenic barriers. Because CpG ODN mimics
DNA sequences of infective microbial agents, ligation
to its TLR led to a transient splenomegaly, likely due
to increased splenic hematopoiesis, teleologically
aimed at combating bacterial or viral infection [28].
Similar to the effect of CpGonCD11b1Gr-11 enrich-
ment observed in our study, accumulation of
CD11b1Gr-11 cells with immune suppressive capa-
bility has been reported previously in various circum-
stances of immune stress, such as in the spleens of
tumor-bearing mice [29,30] or in the peripheral blood
of cancer patients [31], during polymicrobial sepsis
[32] or chronic inflammation [33], and after myelosup-
pressive conditioning by either cyclophosphamide or
irradiation [34,35]. In accordance with our findings,
and as reported by others, the CD11b1Gr-11 cell pop-
ulation is phenotypically heterogenous, consistingTable 4. Impaired T Cell Alloreactivity In Vivo after Donor Pretreatment
T Cell Pretreatment Survival, Days, Median (Range), n GVHD-Related Death GVHD-Free Survivors Chimerism
None 18 (10-118), 17 17/ 17 0/17 NA
IFA 20 (15-54), 11 11/11 0/11 NA
Non-CpG1IFA 22 (16-.250), 9 7/9 2/9 ND
CpG1IFA .250 (107-.250), 14 1/14 13/14 2*/14
NA, not applicable; ND, not done.
T cells were isolated from spleens of naı¨ve or C57 mice pretreated with CpG1IFA 10 days earlier. Pretreatment with IFA or non-CpG1IFA
served as controls. Isolated T cells (3  106) were inoculated intravenously into sublethally irradiated F1 mice. Results were pooled from
2 independent experiments. P 5 .00 for the comparison of the CpG1IFA experimental group versus all other groups.
*65% and 95% chimerism were determined in blood samples obtained 80-100 days after cell inoculation.
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Experimental Group Survival, Days, Median (Range), n GVHD-Related Deaths GVHD-Free Survivors*
Naı¨ve T cells 19 (10-118), 21 21/21 0/17
Naı¨ve T cells1TCD fraction of CpG1IFA .200 (14-.200), 21 1/21 20/21
Naı¨ve C57T cells (3106) were injected into sublethally irradiated F1mice with or without TCD (20 106) cell fraction of spleens derived from
C57 donor mice treated with CpG1IFA 10 days earlier. Results were pooled from 3 independent experiments. All GVHD-free survivors
tested displayed 85%-100% donor cell genotype (H-2b) .170 days after cell inoculation. P 5 .00 for comparison of the 2 experimental
groups.
*GVHD-free survivors were evaluated on day 200 after cell inoculation.mainly of early immature myeloid progenitor cells
[29,36] and lacking the very early CD34 hematopoietic
marker, the B220 B cell marker, and themonocytic and
DC differentiation markers CD14 and CD11c [36].
The increased number of CD11b1Gr-11MSCs is as-
sociated with impaired immune functions, such as a re-
duced number of CD31 cells [29,32,33,36,37] and
diminished proliferative response of T lymphocytes
to mitogenic or alloantigenic stimuli, as was also con-
firmed in the present study. Splenocytes from
CpG1IFA-treatedmice exhibited a significantly lower
response to alloantigens and Con-A stimuli compared
with splenocytes from naı¨ve or non–CpG1IFA-
treated mice. In contrast to naı¨ve cells, spleen cells
from treated donors did not cause GVHD after injec-
tion as either unseparated bulk cells or isolated T cells.
This indicates that in addition to the reduced number
of T cells in treated mice, impaired T cell function also
results from CpG treatment, possibly associated with
down-regulation of the T cell receptor zeta chain, as
has been found in an experimental model of chronic in-
flammation [33].
Both ConA and anti-CD3 antibodies are known to
serve as T cell mitogenic stimulators, but, as shown in
the present study, CpG treatment caused a decreased
ConA response, while anti-CD3 activation remained
unaffected. The different responses of these mitogens
might be due to various aspects of their stimulatory re-
actions (eg, binding to the specific receptor), trigger-
ing various pathways of signal transduction, and the
outcome of production/ secretion of various cyto-
kines, chemokines, or other microenvironmental
agents. Indeed, ConA is a lectin that binds to both T
cells and non–T cells through glucose and mannose
receptors, whereas anti-CD3 antibody is specific and
binds only to T cell receptors expressed exclusively
on T cells. Binding and activation of macrophages
by ConA leads to nitric oxide production, which is be-
lieved to be involved in macrophage-mediated cyto-
toxicity [38,39]. Because splenocytes derived from
CpG-treated mice contained an increased number of
CD11b1 cells, ConA stimulation may have activated
these cells to produce the cytotoxic component nitric
oxide, thereby affecting the proliferation of T cell cul-
tures. It is noteworthy that, as has been reported by
others, because of a differential sensitivity to iron re-quirements, the response to anti-CD3 antibody is
much less affected than the response to ConA in a sit-
uation of ferric deficiency [40]. Changes induced in the
culture might have different effects on the response to
different stimuli.
The activation of various cell subsets by CpG also
has a stimulatory effect on gene expression and pro-
duction of a cytokine pattern, depending on the type
and dose of CpG used for stimulation [41]. The
CpG 1826 used in our study is identified as class B,
which is known for its stimulatory activity on B cells,
NK cells, and monocytes, as well as for its potent abil-
ity to induce proinflammatory and regulatory cyto-
kines derived from these activated cells [2,41-46].
Indeed, as shown in the present study, the secretion
of immunoregulatory IL-10, IL-6 and, to a lesser de-
gree, IFN-g was greater after CpG treatment with
and without IFA than that in the relevant non-CpG
control treatment or naı¨ve cells. The source of these
cytokines might be lymphocytes, NK cells (IFN-g,
IL-10), or monocytes (IL-6), all of which, however,
are known for their immunomodulatory activity that
might affect various cell types, including down-regula-
tion of Th 1 and Th 2 cells. These cytokines are prob-
ably responsible for the reduced mitogenic and
allogeneic responses in vitro and may play a role in
the prevention of alloreactivity in vivo when CpG-
activated donor cells are triggered on inoculation
into the irradiated hosts.
CpG ODN has been applied by others [10] as an
adjuvant capable of inducing preferential Th1 immune
responses. It has been suggested that CpGmay provide
greater immune protection and that it may replace the
toxic mycobacteria included in CFA [12]. Whereas
injection of antigen emulsified in CFA induces
a Th1-dominated response and injection of antigen
emulsified in IFA induces a Th2-dominated response,
the combination of antigen emulsified in IFA and CpG
induces a stronger immune response than either of
these [11]. In the present study as well, an increased
number of double-positive CD11bGr-1 myeloid cells
and greater immunoregulatory cytokine secretion
was observed after inoculation of an admix of CpG
and IFA compared with inoculation by CpG alone;
consequently, we focused more on donor treatment
with CpG1IFA and its mode of action.
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CD11b1 cells provides evidence of the role of these
cells in immunoregulation; however, there is no direct
evidence of their role in vivo. The fact that a TCD
fraction derived from CpG1IFA-treated donors effi-
ciently prevented GVHD allows us to exclude the
role of T immunoregulatory cells in our experimental
model and to regard the TCD fraction as an efficient,
feasible source of immunoregulatory cells when aim-
ing to prevent GVHD in clinical applications. Pheno-
typic analysis of the TCD fraction revealed the
presence of CD11b1Gr-11 cells and the absence of
CD31 or Thy1.21 cells (data not shown). Prevention
of GVHD by pretransplantation donor treatment
with CpG1IFA was the outcome of the reduced num-
ber and functional impairment of T cells, the presence
of enriched MSCs and/or the increased potential for
immunoregulatory cytokine secretion, or a combina-
tion of these factors. Protection from lethal GVHD
clearly was not the result of allograft rejection, because
inoculation of the unseparated splenocytes or TCD
fraction co-injected with naı¨ve T cells led to full and
long-lasting engraftment, with documented chime-
rism in the sublethally irradiated hosts. The finding
that inoculation of TCD fraction alone did not result
in engraftment can be explained by the fact that after
nonmyeloablative conditioning, the number of donor
T cells is critical for stable hematopoietic engraftment
due to facilitation of engraftment by immunocompe-
tent T cells [47].
Although CpG’s adjuvant effect and its ability to
stimulate a Th1-type immune response [7-13] have
been demonstrated, several reports have shown
CpG-induced immunosuppression mediated through
CD191 DCs [48] or through an anti-inflammatory
effect based on a T cell–independent increased level
of IFN-g [49]. CpG’s stimulatory and protective ac-
tivities are both mediated through TLR9 activation,
but insufficient data are available at present to evaluate
the exact circumstances under which these pathways
are triggered [49]. Similarly, it has been shown that
CpG treatment given to irradiated host mice in an ex-
perimental model of acute GVHD caused acceleration
of the allogeneic reaction [44,50], whereas CpG given
to host mice with chronic GVHD conferred a thera-
peutic benefit [45]. CpG given to irradiated hosts in
our model of acute GVHD also proved ineffective in
preventing lethal GVHD [24]. It is important to
note that although these previous studies reported
the effect of CpG treatment on host mice, our strategy
was based on pretransplantation treatment of donors
in a murine model of acute GVHD. We have previ-
ously discussed the rationale and advantages of donor
treatment over host treatment [24], and this approach
has now proven to be most efficient in a murine
GVHD model across fully mismatched MHC
alloantigens.It has been shown that isolated bone marrow–de-
rived CD11b1 DCs given with splenocytes to high-
dose irradiated recipientmice, as well as spleen-derived
CD11b1 DCs administered after nonmyeloablative
conditioning and co-stimulatory blockade, can induce
transplant tolerance without GVHD induction
[51,52]. These findings are in accordance with our ob-
servation of the capability of CD11b1-derived cells to
prevent alloreactivity.
Here we have presented evidence showing that af-
ter CpG treatment, regulation of GVHD is carried out
by myeloid cells, acting as MSCs. However, several
studies have reported immunomodulation of GVHD
achieved by T regulatory CD41CD251 cells [53] or
NK T cells [25]. A comparison of myeloid cells and
regulatory CD41CD251 T cells carried out side by
side in murine experimental models revealed the mye-
loid cells’ superior suppressive strength [36]; however,
their efficacy can be determined only in well- con-
trolled clinical trials. The use of allogeneic cell therapy
in tumor-bearing mice or cancer patients aims to in-
duce a graft-versus-tumor response without inducing
GVHD. Although a graft-versus-leukemia response
is often coexpressed with GVHD, various strategies
are available to achieve effective separation of these re-
activities [51,54]. Thus, it was of utmost importance to
test our strategy of pretransplantation donor treatment
with CpG in tumor-bearing mice. A report on this
study is currently in preparation.
In accordance with our previous observations us-
ing parental C57 cells inoculated into F1 mice [24],
the present study provides further insight into the ef-
fect of CpG pretransplantation donor treatment on
the prevention of GVHD induction when another
strain of donor mice (BALB/c) is used across fully mis-
matched MHC antigen barriers. Detailed phenotypic
and biological activity analysis of cell subset popula-
tions revealed cellular and humoral immunologic
constituents that allow us to explain the mode of ac-
tion and to design an improved defined protocol
with the TCD fraction that also eventually may be
useful in clinical applications. Our data provide evi-
dence of the feasibility of controlling GVHD by pre-
transplantation donor treatment with CpG. Similar to
the triggering of TLR9 by CpG, we have previously
reported the triggering of TLR4 by its ligand LPS.
Appling the same strategy of pretransplantation donor
treatment, a significant (albeit less effective) reduction
of GVHD incidence was observed after LPS donor
treatment [24]. The finding of a substantial accumula-
tion of MSCs in the peripheral blood after CpG treat-
ment facilitates the collection of these cells and makes
our strategy feasible for clinical application. This
finding may justify preliminary clinical application
of a similar strategy in patients with an absolute indi-
cation for stem cell transplantation with genetic disor-
ders or malignant diseases at risk for GVHD or
CpG-Induced Myeloid Suppressor Cells 983otherwise at risk due to long-lasting posttransplanta-
tion immunosuppression with consenting donors, be-
cause treatment with CpG with or without IFA before
harvesting of stem cells in a normal donor is certainly
less hazardous than uncontrolled GVHD in the recip-
ient.
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